55 results about "Ovulation times" patented technology

A contraceptive device for placement in a fallopian tube includes expanding distal and proximal anchor members and an expandable elongate member connecting the distal anchor member to the proximal anchor member. An expandable material is disposed on at least a portion of the contraceptive device, whereupon delivery of the contraceptive device, the expandable material expands to completely occlude the fallopian tube. The expandable material may contain a drug, therapeutic agent, or hormone which is released over time to occlude or otherwise prevent the passage of spermazoa through the fallopian tube, or prevent ovulation. The contraceptive device may be delivered non-operatively and provide complete sterilization within a period of days. The device and delivery method obviates the need for follow-up visits to confirm closure of the fallopian tubes.

The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulator include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.

A method of diagnosing ovulation in a female mammal comprises measuring the pH of the ectocervix of the female mammal and comparing the pH measured of the ectocervix to a reference value.

A method for synchronizing ovulation in sows and gilts by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (hCG), analogues, derivatives, agonists or combinations thereof is administered to an open sow post weaning at a specific time to stimulate ovulation of mature responsive follicles. The sow is then bred, without heat detection, at a specific subsequent timed interval after injection with hormone, with one or two artificial or natural breedings. In gilts, the hormone is injected at a timed interval from onset of estrus or at a specific timed interval following Prostaglandin F2a for those gilts which have been held in a state of pseudopregnancy.

The invention relates to a drug for treating polycystic ovarian syndrome. The drug is characterized by comprising an oral medicine and an enema medicine, wherein the oral medicine comprises 15 g of common curculigo rhizome, 10 g of epimedium, 15 g of common cnidium fruit, 15 g of medicinal morinda root, 15 g of dodder, 15 g of glossy privet fruit, 15 g of medlar, 10 g of prepared rhizome of rehmannia, 15 g of angelica, 15 g of szechwan lovage rhizome, 15 g of salvia miltiorrhiza, 15 g of dangshen, 15 g of stir-fried ovate atractylodes root, 15 g of tuckahoe, 30 g of common yam rhizome, 15 g of pinellia, 12 g of seasoned orange peel, and 15 g of officinal magnolia bark, and the enema medicine comprises 15 g of peach seed, 10 g of safflower, 15 g of common burreed tuber, 12 g of cassiabarktree twig, 15 g of trumpetweed, 15 g of speranskia tuberculata, 15 g of common selfheal spike, 15 g of Chinese honeylocust spine, 15 g of szechwan lovage rhizome, 15 g of seaweed, and 15 g of kelp. According to the present invention, treatment philosophy of combination of the oral medicine and the enema medicine is adopted, and blood circulation activating, blood stasis dissipating, swelling subsiding, and stagnation eliminating are adopted to reduce intumescent ovary and thin ovarian follicle, such that ovulation easily occurs.

Metastin, compounds that promote the activity of metastin or its receptors and the like are excellent gonadal function improving agents, ovulation inducers or promoters, gonadotropic hormone secretion promoters, gonadotropic hormone secretion inhibitors, sex hormone secretion promoters, sex hormone secretion inhibitors, etc., and can be used as agents for preventing/treating sterility, hormone-sensitive cancers, endometriosis, etc. Metastin and its receptors are useful for screening for these pharmaceuticals.

A method for detecting the onset of ovulation in a female mammal is provided. The method comprises contacting mouth air of the female mammal with an arylmethane test chromogen in an amount effective to undergo a rapid and detectable color change in the presence of one or more volatile sulfur compounds. The color of the test chromogen is compared to a control color that corresponds to a pre-ovulatory sulfur content. The difference in color between the test chromogen and the control color is correlated to the onset of ovulation.

In a new pharmaceutical combination, the herb, Vitex agnus-castus (chasteberry), enhances hormone balance by increasing progesterone release and, therefore, ovulation frequency. The antioxidants, green tea, vitamin E, and selenium, improve overall reproductive health. L-arginine, an amino acid, stimulates the reproductive organs by improving circulation. Folic acid, vitamins B6 and B12, iron, zinc and magnesium help promote womens' fertility. Sperms are highly susceptible to free radical or oxidative damage from environmental toxicants and natural aging. Vitamins C and E, coenzyme Q10 and selenium are all potent antioxidants that help improve sperm counts and quality. Ferulic acid, an antioxidant found in Dong quai, also improves sperm quality. Zinc and B vitamins (B6, B12 and folate) are critical nutrients in male reproductive systems for hormone metabolism, sperm formation and motility. The amino acid, L-carnitine, promotes formation of healthy sperm.

The present invention relates to a method and composition for use in treating a condition that benefits from the reduction of hepatic and/or visceral fat, such as polycystic ovary syndrome in adolescent girls or women of childbearing age, involving the use of spironolactone, pioglitazone and metformin.

The invention discloses a traditional Chinese medicine composition for treating hypomenorrhea. The traditional Chinese medicine composition consists of the following traditional Chinese medicine raw materials in parts by weight: 15 parts of cuscuta chinensis, 15 parts of barbary wolfberry fruit, 9 parts of mistletoe, 15 parts of himalayan teasel root, 12 parts of eucommia ulmoides, 15 parts of prepared fleece flower root, 12 parts of Chinese yam, 10 parts of codonopsis pilosula, 15 parts of semen coicis, 12 parts of rehmannia glutinosa, 12 parts of Chinese angelica, 9 parts of white paeony root, 12 parts of rhizoma cyperi, 12 parts of radix bupleuri, 9 parts of red paeony root, 20 parts of salvia miltiorrhiza, 15 parts of caulis spatholobi, 15 parts of achyranthes bidentata amd 6 parts of prepared liquorice root. The traditional Chinese medicine has the basic effects of tonifying the kidney and replenishing essence and has the effects of relieving liver for smooth Qi and promoting blood circulation to remove blood stasis; and modern pharmacological studies prove that the reproductive axis of hypothalamus-hypophysis-ovary-uterus can be adjusted through the medicine, ovulation and luteal development are promoted, the ovary microcirculation is improved, and the medicine has the obvious effect of treating hypomenorrhea.

The invention is a hand held ovulation predictor device, which includes an ovulation predictor device body, an optical subassembly containing one or more aspheric lenses, an electronics assembly, a battery compartment, a light source and, optionally, a cover. The preferred embodiment of this invention is one in which the one or more lenses are aspheric.

The invention discloses a method for preparing an inhibin genetic engineering regulation antigen, which comprises the following steps: cloning an inhibin encoding gene; making use of the inhibin encoding gene to prepare an inhibin recombinant fusion protein; and making use of the inhibin recombinant fusion protein to prepare the inhibin genetic engineering regulation antigen. The method for preparing the inhibin genetic engineering regulation antigen has the advantages of simplicity, high purity, good immunogenicity, low price and the like; the inhibin genetic engineering regulation antigen prepared by the method does not have toxicity, pathogenicity and drug residue, is harmless to human and animals, has no adverse effect on consumers, can improve the ovulation rate and the litter size, improve utilization ratio of a superovulation embryo, promote the sexual maturation so as to improve the reproduction and the like.

A method of using a medical food to increase human fertility. This medical food consists of transfer factor, lactic acid generating bacteria, and glucans in appropriate combinations. The medical food, administered correctly, reduces cortisol levels. Progesterone increases as cortisol decreases, and progesterone is needed to support pregnancy and ovulation. Dosage amounts are adjusted for client weight. Typically, consumption of the medical food begins several days before planned conception.

The present invention relates to methods of increasing likelihood of conception, treatment of low fecundity and/or providing menstrual cycle control without suppressing ovulation in a female comprising administering an effective dose of at least one estrogen and at least one progestin within a treatment period of at least 21 days to 35 days or multiple periods thereof. Furthermore, the invention relates to the combination of at least one estrogen and at least one progestin for the preparation of a medicament to be used in the abovementioned indications. A pharmaceutical kit, according to the invention, comprises 21 to 35 dosage units or a multiple of 21 to 35 dosage units, wherein a first section comprises at most 21 dosage units of at least one estrogen; and a second section comprises from 2 to 34 dosage units of at least one estrogen and from 2 to 34 dosage units of at least one progestin or comprises from 2 to 34 dosage units of at least one estrogen and at least one progestin provided that in each dosage unit containing a progestin or a progestin and an estrogen the progestin is in a non-ovulation inhibiting amount; and and optionally a third section comprises at most 10 dosages of a pharmaceutically acceptable placebo or a blank.

A method of treating a human female with an androgen and a gonadotropin to improve at least one of the human female's infertility, reproductive outcomes and oocyte yield is disclosed. The method may include treating the female with an androgen and a gonadotropin in combination. The androgen may be administered for more than six weeks and the gonadotropin may be administered in a regular low dosage over a period of time longer than two weeks. The method may include inducing ovulation in the female by administering gonadotropins to stimulate ovulation and/or induce ovulation. The method may include multiple additional inductions of ovulation, each within 120 days of the previous induction of ovulation.

Novel phenothiazine derivatives and their use in the treatment of diabetes mellitus (type I and type II), and as an ovulation inhibitor (contraceptive), cancer chemotherapeutic and/or prophylactic agent, anti-obesity drug (body weight regulator), and immunostimulant.

Disclosed herein is an ovulation detection apparatus. The ovulation detection apparatus includes a skin resistance measuring means for measuring the resistance value of the skin of fingers, a body temperature measuring means for measuring the temperature value of a tongue, and a potential difference measuring means for measuring the potential difference value of the mucus of a mouth. In the ovulation detection apparatus, a control means doubly determines whether an examinee is ovulating by selecting reference body temperature and potential difference values according to a measured skin resistance value and comparing measured body temperature and potential difference values with the reference body temperature and potential difference values, respectively. The ovulation detection apparatus further includes an output means for outputting the determination result of the control means so as to allow a user to recognize it, a power source for supplying electricity to the means, and an on-off switch for selectively turning on and off electricity supplied from the power source.

This invention relates to methods to predict and monitor ovulation and fertility in female mammals by measuring the level of free salivary estradiol. Such information may be used to identify the appropriate timing for egg retrieval prior to in vitro fertilization (IVF), insemination procedures, natural or otherwise, and the timing for transfer of embryos. The ability to monitor salivary estradiol levels throughout the estrous cycle, with the optional application of an algorithm, will aid in identifying the peak time of fertility.

The present invention is directed to the identification of a novel domain of functional significance on the GDF-9 and GDF-9B molecules and to peptides and antibodies which interact with the domain to modulate the biological activity of these molecules to alter mammalian ovarian function and ovulation rate.

The invention discloses a traditional Chinese medicine for assistant treatment of fallopian tube obstructive infertility and a preparation method thereof. The traditional Chinese medicine is prepared from dodder, dipsacus root, herba taxilli, eucommia, prepared rehmannia, white peony root, ligusticum wallichii, peach kernel, salviae miltiorrhizae and Chinese angelica by a traditional Chinese medicinal process. The traditional Chinese medicine is scientific and reasonable in process and easy to operate, can improve the internal environment of a body to enable the body to be balanced in yin and yang and invigorated in vital energy and blood, and leads coordination of organ functions, so that the ovulation function can be recovered. The traditional Chinese medicine has an effect of assistant treatment to patients after tubal repatancy and plastic surgery, the postoperative recanalization rate and pregnancy rate can be improved, and an economical and effective method for treating fallopian tube obstructive infertility is provided to patients.

The invention provides methods and kits for monitoring the status of women's health, including HRT monitoring and determination or diagnosis of ovulation, contraception, pregnancy, menopause, polycystic ovarian disease, and female sexual dysfunction. The method comprises the steps of: (a) collecting a tear fluid from a female human; (b) determining the tear concentration of at least one hormone of relevance to female fertility, sexual differentiation or sexual dysfunction in a female human, wherein the tear concentration is diagnostics of the status of women's health.